317 related articles for article (PubMed ID: 30333413)
1. Crohn's Disease with Mesalazine Allergy that Was Difficult to Differentiate from Comorbid Ulcerative Colitis.
Tsuboi R; Matsumoto S; Miyatani H; Mashima H
Intern Med; 2019 Mar; 58(5):649-654. PubMed ID: 30333413
[TBL] [Abstract][Full Text] [Related]
2. Mesalazine allergy in a boy with ulcerative colitis: clinical usefulness of mucosal biopsy criteria.
Wada S; Kumagai H; Yokoyama K; Ito T; Miyauchi A; Sakamoto S; Imagawa T; Tulyeu J; Tanaka M; Yamagata T
Clin J Gastroenterol; 2016 Oct; 9(5):302-5. PubMed ID: 27503129
[TBL] [Abstract][Full Text] [Related]
3. Prolonged-release mesalazine: a review of its therapeutic potential in ulcerative colitis and Crohn's disease.
Clemett D; Markham A
Drugs; 2000 Apr; 59(4):929-56. PubMed ID: 10804042
[TBL] [Abstract][Full Text] [Related]
4. [Mesalazine-induced eosinophilic pneumonia in a patient with Crohn's disease].
Park JE; Hwangbo Y; Chang R; Chang YW; Jang JY; Kim BH; Dong SH; Kim HJ
Korean J Gastroenterol; 2009 Feb; 53(2):116-20. PubMed ID: 19237838
[TBL] [Abstract][Full Text] [Related]
5. [Mesalazine and sulphasalazine for Crohn's disease: few indications, severe adverse reactions].
Uittenbogaart SB; Klemt-Kropp M
Ned Tijdschr Geneeskd; 2011; 155(48):A3842. PubMed ID: 22152414
[TBL] [Abstract][Full Text] [Related]
6. A Case of Right-Sided Ulcerative Colitis with Mesalamine-Induced Hypersensitivity Reactions.
Hirono H; Watanabe K; Hasegawa K; Honma T; Ajioka Y; Ohkoshi S
Am J Case Rep; 2018 May; 19():623-629. PubMed ID: 29849018
[TBL] [Abstract][Full Text] [Related]
7. Recent advances in clinical practice: a systematic review of isolated colonic Crohn's disease: the third IBD?
Subramanian S; Ekbom A; Rhodes JM
Gut; 2017 Feb; 66(2):362-381. PubMed ID: 27802156
[TBL] [Abstract][Full Text] [Related]
8. Mesalazine-induced psoriasis in patients with inflammatory bowel diseases.
Di Cesare A; Fidanza R; Riitano A; Fargnoli MC; Peris K
Eur J Dermatol; 2011; 21(5):784-5. PubMed ID: 21697068
[No Abstract] [Full Text] [Related]
9. Mesalazine-induced multi-organ hypersensitivity.
Sposato B; Allegri MP; Riccardi MP; Chigiotti S; Nencioni C; Ricciardi B; Carli T; Cresti A; Perari MG; Migliorini MG; Toti M
Clin Drug Investig; 2010; 30(6):413-7. PubMed ID: 20441247
[TBL] [Abstract][Full Text] [Related]
10. [Acute pancreatitis--adverse effect of 5-aminosalicylic acid (mesalazine) in various galenic dosage forms].
Schwörer H; Ramadori G
Dtsch Med Wochenschr; 2000 Nov; 125(44):1328-30. PubMed ID: 11109415
[TBL] [Abstract][Full Text] [Related]
11. Mesalazine for the treatment of inflammatory bowel disease.
Criscuoli V; Modesto I; Orlando A; Cottone M
Expert Opin Pharmacother; 2013 Aug; 14(12):1669-78. PubMed ID: 23767798
[TBL] [Abstract][Full Text] [Related]
12. [Case of ulcerative colitis induced by mesalazine with acute aggravated colitis-like symptoms].
Inatsuchi S; Nakajima T; Yoshio Y; Entani A; Okada K
Nihon Shokakibyo Gakkai Zasshi; 2004 Sep; 101(9):989-92. PubMed ID: 15478662
[No Abstract] [Full Text] [Related]
13. [Angioedema in Crohn's disease possibly due to mesalazine].
Nguyen-Khac E; Le Baron F; Thevenot T; Tiry-Lescut C; Tiry F
Gastroenterol Clin Biol; 2002 May; 26(5):535-6. PubMed ID: 12122371
[No Abstract] [Full Text] [Related]
14. [Two cases of drug-induced intrathoracic lesions caused by mesalazine in patients with ulcerative colitis].
Machida H; Shinohara T; Hatakeyama N; Inayama M; Hosokawa E; Ogushi F
Nihon Kokyuki Gakkai Zasshi; 2011 Jul; 49(7):538-42. PubMed ID: 21842693
[TBL] [Abstract][Full Text] [Related]
15. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
[TBL] [Abstract][Full Text] [Related]
16. Mesalazine-induced Pleuropericarditis in a Patient with Crohn's Disease.
Kiyomatsu H; Kawai K; Tanaka T; Tanaka J; Kiyomatsu T; Nozawa H; Kanazawa T; Kazama S; Ishihara S; Yamaguchi H; Sunami E; Watanabe T
Intern Med; 2015; 54(13):1605-8. PubMed ID: 26134190
[TBL] [Abstract][Full Text] [Related]
17. Clinical pharmacokinetics of slow release mesalazine.
De Vos M
Clin Pharmacokinet; 2000 Aug; 39(2):85-97. PubMed ID: 10976656
[TBL] [Abstract][Full Text] [Related]
18. High-dose mesalazine treatment for ulcerative colitis patients who relapse under low-dose maintenance therapy.
Yamamoto T; Umegae S; Matsumoto K
Dig Liver Dis; 2011 May; 43(5):386-90. PubMed ID: 21195041
[TBL] [Abstract][Full Text] [Related]
19. [Mesalazine-related interstitial lung disease: an under-diagnosed effect?].
Auffret M; Béné J; Lambert M; Gautier S
Therapie; 2014; 69(6):531-2. PubMed ID: 25320942
[TBL] [Abstract][Full Text] [Related]
20. Mesalazine allergy and an attempt at desensitization therapy in patients with inflammatory bowel disease.
Matsumoto S; Mashima H
Sci Rep; 2020 Dec; 10(1):22176. PubMed ID: 33335169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
